Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines

Toyoaki Hida, Ken Ichi Kozaki, Hideki Muramatsu, Akira Masuda, Shigeki Shimizu, Tetsuya Mitsudomi, Takahiko Sugiura, Makoto Ogawa, Takashi Takahashi

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

In recent years, a combination of two demographic phenomena, an increase in the number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggest that the responsiveness of non-small cell lung cancer to COX-2 inhibitors does not require the presence of wild-type p53, but may be influenced by the degree of COX-2 expression. In addition, we found that nimesulide, when used in combination at clinically achievable concentrations, reduced the IC50 values of various anticancer agents by up to 77%, although the level of reduction varied considerably. Because our previous studies have indicated a significantly increased COX-2 expression in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest. In conjunction with the recent development of next generation, highly selective COX-2 inhibitors, they can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer agents for the treatment of high-risk patients without compromising their quality of life.

Original languageEnglish
Pages (from-to)2006-2011
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number5
Publication statusPublished - May 2000
Externally publishedYes

Fingerprint

nimesulide
Cyclooxygenase 2 Inhibitors
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Cyclooxygenase 2
Apoptosis
Cell Line
Lung Neoplasms
Inhibitory Concentration 50
Adenocarcinoma
Therapeutics
Quality of Life
Demography
Incidence
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hida, T., Kozaki, K. I., Muramatsu, H., Masuda, A., Shimizu, S., Mitsudomi, T., ... Takahashi, T. (2000). Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clinical Cancer Research, 6(5), 2006-2011.

Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. / Hida, Toyoaki; Kozaki, Ken Ichi; Muramatsu, Hideki; Masuda, Akira; Shimizu, Shigeki; Mitsudomi, Tetsuya; Sugiura, Takahiko; Ogawa, Makoto; Takahashi, Takashi.

In: Clinical Cancer Research, Vol. 6, No. 5, 05.2000, p. 2006-2011.

Research output: Contribution to journalArticle

Hida, T, Kozaki, KI, Muramatsu, H, Masuda, A, Shimizu, S, Mitsudomi, T, Sugiura, T, Ogawa, M & Takahashi, T 2000, 'Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines', Clinical Cancer Research, vol. 6, no. 5, pp. 2006-2011.
Hida, Toyoaki ; Kozaki, Ken Ichi ; Muramatsu, Hideki ; Masuda, Akira ; Shimizu, Shigeki ; Mitsudomi, Tetsuya ; Sugiura, Takahiko ; Ogawa, Makoto ; Takahashi, Takashi. / Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 5. pp. 2006-2011.
@article{43bac10be4704539b85edb44b44d0c7f,
title = "Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines",
abstract = "In recent years, a combination of two demographic phenomena, an increase in the number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggest that the responsiveness of non-small cell lung cancer to COX-2 inhibitors does not require the presence of wild-type p53, but may be influenced by the degree of COX-2 expression. In addition, we found that nimesulide, when used in combination at clinically achievable concentrations, reduced the IC50 values of various anticancer agents by up to 77{\%}, although the level of reduction varied considerably. Because our previous studies have indicated a significantly increased COX-2 expression in up to 70{\%} of adenocarcinoma cases, the present findings are of great clinical interest. In conjunction with the recent development of next generation, highly selective COX-2 inhibitors, they can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer agents for the treatment of high-risk patients without compromising their quality of life.",
author = "Toyoaki Hida and Kozaki, {Ken Ichi} and Hideki Muramatsu and Akira Masuda and Shigeki Shimizu and Tetsuya Mitsudomi and Takahiko Sugiura and Makoto Ogawa and Takashi Takahashi",
year = "2000",
month = "5",
language = "English",
volume = "6",
pages = "2006--2011",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines

AU - Hida, Toyoaki

AU - Kozaki, Ken Ichi

AU - Muramatsu, Hideki

AU - Masuda, Akira

AU - Shimizu, Shigeki

AU - Mitsudomi, Tetsuya

AU - Sugiura, Takahiko

AU - Ogawa, Makoto

AU - Takahashi, Takashi

PY - 2000/5

Y1 - 2000/5

N2 - In recent years, a combination of two demographic phenomena, an increase in the number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggest that the responsiveness of non-small cell lung cancer to COX-2 inhibitors does not require the presence of wild-type p53, but may be influenced by the degree of COX-2 expression. In addition, we found that nimesulide, when used in combination at clinically achievable concentrations, reduced the IC50 values of various anticancer agents by up to 77%, although the level of reduction varied considerably. Because our previous studies have indicated a significantly increased COX-2 expression in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest. In conjunction with the recent development of next generation, highly selective COX-2 inhibitors, they can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer agents for the treatment of high-risk patients without compromising their quality of life.

AB - In recent years, a combination of two demographic phenomena, an increase in the number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Our study shows that a cyclooxygenase (COX)-2 inhibitor, nimesulide, can inhibit proliferation of non-small cell lung cancer cell lines in vitro in a dose-dependent manner, in part by inducing apoptosis even at clinically achievable low concentrations. Our observations also suggest that the responsiveness of non-small cell lung cancer to COX-2 inhibitors does not require the presence of wild-type p53, but may be influenced by the degree of COX-2 expression. In addition, we found that nimesulide, when used in combination at clinically achievable concentrations, reduced the IC50 values of various anticancer agents by up to 77%, although the level of reduction varied considerably. Because our previous studies have indicated a significantly increased COX-2 expression in up to 70% of adenocarcinoma cases, the present findings are of great clinical interest. In conjunction with the recent development of next generation, highly selective COX-2 inhibitors, they can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer agents for the treatment of high-risk patients without compromising their quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0034026144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034026144&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 2006

EP - 2011

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -